Neoleukin Therapeutics Email Format

Biotechnology ResearchWashington, United States51-200 Employees

Neoleukin Therapeutics traces its origins to the University of Washington Institute for Protein Design and began operations in January 2019, pursuing immunotherapies developed through engineered proteins designed from first principles. In December 2023, Neoleukin completed a merger with Neurogene Inc., a clinical-stage company focused on delivering genetic medicines for rare neurological diseases.

Based in Seattle, Washington, the company sits in the mid-sized segment of the biotechnology research sector. The merged entity combines Neurogene’s clinical focus with Neoleukin’s protein-design background to address therapeutic approaches for neurological genetic conditions. In April 2026, the company announced leadership changes, naming Christy Shafer as chief commercial officer and adding Christine Mikail to its board.

Sign up for free to view info

Company overview Employee directory